Literature DB >> 12669205

[Topical corticosteroids versus topical inhibitors of calcineurin].

R Niedner1.   

Abstract

Topical corticosteroids (TCC) have significantly shaped dermatological therapy for five decades. A few months ago the TCC were joined by competition, the topical inhibitors of calcineurin (TIC), wrongly termed topical immunomodulators. The present paper reviews the pharmacological effects and clinical efficacy of TIC, compares the risks, benefits and costs of those two groups of topical drugs and develops a position on the use of TIC. While TIC have ushered in a new era of topical anti-inflammatory therapy, the age of TCC is far from over.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669205     DOI: 10.1007/s00105-003-0488-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  19 in total

1.  A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus.

Authors:  Y Suga; R Tsuboi; Y Hashimoto; T Yoshiike; H Ogawa
Journal:  J Am Acad Dermatol       Date:  2000-03       Impact factor: 11.527

2.  Topical tacrolimus for chronic actinic dermatitis.

Authors:  Yasushi Suga; Yukiko Hashimoto; Shouichi Matsuba; Masayuki Mizoguchi; Hideoki Ogawa
Journal:  J Am Acad Dermatol       Date:  2002-02       Impact factor: 11.527

Review 3.  Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis.

Authors:  Paul Nghiem; Greg Pearson; Richard G Langley
Journal:  J Am Acad Dermatol       Date:  2002-02       Impact factor: 11.527

4.  Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus.

Authors:  F Kaliakatsou; T A Hodgson; J D Lewsey; A M Hegarty; A G Murphy; S R Porter
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

5.  Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial.

Authors:  Christina Schnopp; Roland Remling; Matthias Möhrenschlager; Lorenz Weigl; Johannes Ring; Dietrich Abeck
Journal:  J Am Acad Dermatol       Date:  2002-01       Impact factor: 11.527

6.  Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.

Authors:  Lawrence F Eichenfield; Anne W Lucky; Mark Boguniewicz; Richard G B Langley; Robert Cherill; Katharine Marshall; Christopher Bush; Michael Graeber
Journal:  J Am Acad Dermatol       Date:  2002-04       Impact factor: 11.527

Review 7.  [Pimecrolimus (SDZ ASM 981). Current state of research].

Authors:  J Dissemond; M Goos; S N Wagner
Journal:  Dtsch Med Wochenschr       Date:  2002-05-31       Impact factor: 0.628

8.  [Immunosuppressive macrolides and their use in dermatology].

Authors:  E C Bornhövd; E Schuller; T Bieber; A Wollenberg
Journal:  Hautarzt       Date:  2000-09       Impact factor: 0.751

9.  Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report.

Authors:  D Goldman
Journal:  J Am Acad Dermatol       Date:  2001-06       Impact factor: 11.527

10.  The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion.

Authors:  U Mrowietz; M Graeber; M Bräutigam; M Thurston; A Wagenaar; G Weidinger; E Christophers
Journal:  Br J Dermatol       Date:  1998-12       Impact factor: 9.302

View more
  1 in total

Review 1.  [Systemic therapy of atopic dermatitis].

Authors:  A Heratizadeh; K Breuer; A Kapp; T Werfel
Journal:  Hautarzt       Date:  2003-10       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.